title: Hepcidin and GDF15 in anemia of multiple myeloma.
abstract: Multiple myeloma (MM) is a malignant disease of plasma cells and is often accompanied by anemia which may influence its progression and survival. The mechanism of anemia of chronic disease (ACD) in which iron homeostasis is impaired underlies that of MM-related anemia. In this study, we analyzed the role of hepcidin which is the main mediator of ACD and ACD-related cytokines in peripheral blood of MM patients. We showed that HAMP mRNA and growth differentiation factors 15 (GDF15) mRNA expressions in peripheral blood mononuclear cells (PBMCs) and plasma hepcidin, GDF15, interleukin-6 and erythropoietin in MM patients all increased significantly as compared to those in controls. In MM patients, the expression of HAMP mRNA showed a positive correlation with serum ferritin level, and a negative correlation with hemoglobin level. The levels of plasma hepcidin and GDF15 were significantly decreased in MM patients who achieved complete remission after six cycles VD (bortezomib + dexamethasone) regimen chemotherapy. These data indicated that overexpression of HAMP mRNA in PBMCs significantly correlated with increased plasma hepcidin level and may be involved in the pathogenesis of MM-related anemia. Furthermore, the levels of plasma hepcidin and GDF15 may be valuable in assessing the progress of MM.
authors: Department of Hematology, General Hospital, Tianjin Medical University, 154 Anshandao, Heping District, Tianjin, 300052, People's Republic of China, meishuchong716@163.com.
authors: Shuchong
authors: S
authors: Mei
authors: Huaquan
authors: H
authors: Wang
authors: Rong
authors: R
authors: Fu
authors: Wen
authors: W
authors: Qu
authors: Limin
authors: L
authors: Xing
authors: Guojin
authors: G
authors: Wang
authors: Jia
authors: J
authors: Song
authors: Hong
authors: H
authors: Liu
authors: Lijuan
authors: L
authors: Li
authors: Xiaoming
authors: X
authors: Wang
authors: Yuhong
authors: Y
authors: Wu
authors: Jin
authors: J
authors: Guan
authors: Erbao
authors: E
authors: Ruan
authors: Zonghong
authors: Z
authors: Shao
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000150:complications / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D002908:Chronic Disease; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D005293:Ferritins / Q000097:blood / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D055436:Growth Differentiation Factor 15 / Q000097:blood / Q000235:genetics*; D006454:Hemoglobins / Q000235:genetics / Q000378:metabolism; D064451:Hepcidins / Q000097:blood / Q000235:genetics*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D011719:Pyrazines / Q000627:therapeutic use; D012333:RNA, Messenger / Q000097:blood / Q000235:genetics*; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; C526140:GDF15 protein, human; D055436:Growth Differentiation Factor 15; C578702:HAMP protein, human; D006454:Hemoglobins; D064451:Hepcidins; D011719:Pyrazines; D012333:RNA, Messenger; D000069286:Bortezomib; D003907:Dexamethasone; D005293:Ferritins